NCT05567029View on ClinicalTrials.gov

Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

April 20, 2023

Study Completion Date

April 20, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

Risankizumab Dose A

Prefilled Syringe

DRUG

Risankizumab Dose B

Prefilled Syringe

Trial Locations (5)

33014

Clinical Pharmacology of Miami /ID# 250099, Miami

60030

Acpru /Id# 249681, Grayslake

65802

Bio-Kinetic Clinical Applications, LLC /ID# 250181, Springfield

78744

PPD Clinical Research Unit - Austin /ID# 250672, Austin

92801-2658

Anaheim Clinical Trials LLC /ID# 250098, Anaheim

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY

NCT05567029 - Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers. | Biotech Hunter | Biotech Hunter